--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing ... announces the publication of a study titled "Keloid Excision With Primary Closure Combined ...

Scar Removal Treatment Market Market CAGR for scar removal treatment is driven by the technological advancements in scar treatment, and gro ...

According to the American Academy of Dermatology, those with more melanin in their skin may be more prone to keloid. They also note that being on certain medications or having certain medical ...

Three women who were housed at a now-closed Detroit youth treatment center have filed a lawsuit, accusing a man who was a ...

Discover the steps for successful laser hair removal on Black skin, including the exact lasers to request and vital ...

In addition, posters have been presented at medical and scientific conferences on TDI’s application ... development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its ...

Sensus Healthcare, Inc. , a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, ...

According to the American Academy of Dermatology, those with more melanin in their skin may be more prone to keloid. They ...

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) had its price objective cut by equities research analysts at Lake Street Capital from $18.00 to $13.00 in a report issued on Tuesday,Benzinga reports.

pre-existing medical conditions interfering with treatment or a history of adverse reactions to the injection. This scoping review examined studies pertaining to HTSs, keloids and the ILCSI, with a ...